Our Services
Medical Information
Helpful Resources
Published on: 4/24/2026
Zepbound often causes diarrhea by slowing gastric emptying, altering gut motility, increasing intestinal secretion, and shifting the microbiome, with most cases emerging in the first 4 to 6 weeks but usually improving as your body adjusts. Most mild to moderate cases can be managed through slower dose titration, simple dietary modifications, hydration, and over-the-counter remedies, but persistent or severe symptoms may require discussing alternative medications with your healthcare provider.
There are several factors to consider. See below for the complete answer, including important details on risk factors, warning signs, and next steps.
Diarrhea is one of the most commonly reported side effects of Zepbound (tirzepatide), a dual GIP/GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management. If you've wondered "why does Zepbound cause diarrhea," you're not alone. Understanding the science behind this reaction—and knowing when to manage it versus when to discuss switching medications—can help you stay on track with your health goals without unnecessary discomfort.
Zepbound's mechanism of action explains much of its gastrointestinal impact:
Together, these factors explain why nearly 10–20% of clinical trial participants experienced diarrhea—usually mild to moderate in severity—after starting or increasing a Zepbound dose.
According to the FDA-approved prescribing information and peer-reviewed studies:
Diarrhea often resolves on its own as your body adjusts, but persistent or severe cases require proactive management.
Some factors may increase your likelihood of significant diarrhea on Zepbound:
Watch for warning signs that warrant immediate medical attention:
Before considering a medication switch, many patients can manage Zepbound-related diarrhea with simple strategies:
If diarrhea is mild and improving within a week or two, it's reasonable to continue Zepbound with these supportive measures.
Switching off Zepbound may be appropriate if:
Discuss alternative therapies with your healthcare provider—options include other GLP-1 agonists, SGLT2 inhibitors, or different classes of diabetes/weight-loss medications.
Always keep your doctor informed about any side effect that:
If you're unsure whether your symptoms are serious, try using a Medically approved LLM Symptom Checker Chat Bot to help assess your symptoms and determine if immediate medical attention is needed.
When you speak to your doctor about diarrhea on Zepbound:
Diarrhea with Zepbound is common but often manageable without stopping therapy. Understanding "why does Zepbound cause diarrhea" can empower you to:
If at any point your diarrhea is severe, persistent, or accompanied by alarming symptoms, please speak to a doctor right away. Your health and comfort matter—don't hesitate to seek professional care.
(References)
* Xu Y, Xu S, Liu Y, Li C, Fu M, Chen C, Shi X. Safety and tolerability of tirzepatide for the treatment of obesity: A systematic review and meta-analysis of randomized controlled trials. Front Endocrinol (Lausanne). 2023 Aug 31;14:1255554. doi: 10.3389/fendo.2023.1255554. PMID: 37651076; PMCID: PMC10499690.
* O'Neil PM, Aroda VR, Chaudhri AN, Davies M, Frias JP, Lingvay I, Mosenzon O, Rosenstock J, Rubino DM, Van Gaal L, Wadden TA, Zoungas S, Kushner RF. Tirzepatide for the treatment of type 2 diabetes and obesity: a review of efficacy and safety. Lancet Diabetes Endocrinol. 2023 Jul;11(7):499-511. doi: 10.1016/S2213-8587(23)00075-8. Epub 2023 Apr 5. PMID: 37021319.
* Chaurasia A, Keshari R, Singh SK. Tirzepatide: A Novel Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes and Obesity. J Assoc Physicians India. 2023 Jan;71(1):16-18. PMID: 36696700.
* El-Sayed M, El-Said HM, El-Abd Y, Al-Balah A, El-Hussiny M, Elgabalawy H. Tirzepatide, a GIP/GLP-1 receptor co-agonist, for the treatment of obesity: a systematic review and meta-analysis of randomized controlled trials. Obes Rev. 2024 Feb;25(2):e13636. doi: 10.1111/obr.13636. Epub 2024 Feb 5. PMID: 38321683.
* Al-Daghri N, Al-Attas O, El-Sayed N, Alkhattabi S, Al-Fadhli S, Al-Yami AM, Al-Saleh Y, Al-Qahtani A. Gastrointestinal Side Effects of GLP-1 Receptor Agonists and Co-Agonists: A Systematic Review and Meta-Analysis. Int J Mol Sci. 2023 Jul 12;24(14):11409. doi: 10.3390/ijms241411409. PMID: 37456729; PMCID: PMC10381017.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.